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chronic myelogenous leukemia cells harboring 
T315I mutation by blocking NF-κB signaling and 
depleting Bcr-Abl
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Abstract
Background: Chronic myelogenous leukemia (CML) is characterized by the chimeric tyrosine kinase Bcr-Abl. Bcr-Abl-
T315I is the notorious point mutation that causes resistance to imatinib and the second generation tyrosine kinase 
inhibitors, leading to poor prognosis. CML blasts have constitutive p65 (RelA NF-κB) transcriptional activity, and NF-κB 
may be a potential target for molecular therapies in CML that may also be effective against CML cells with Bcr-Abl-
T315I.
Results: In this report, we discovered that pristimerin, a quinonemethide triterpenoid isolated from Celastraceae and 
Hippocrateaceae, inhibited growth and induced apoptosis in CML cells, including the cells harboring Bcr-Abl-T315I 
mutation. Additionally, pristimerin inhibited the growth of imatinib-resistant Bcr-Abl-T315I xenografts in nude mice. 
Pristimerin blocked the TNFα-induced IκBα phosphorylation, translocation of p65, and expression of NF-κB-regulated 
genes. Pristimerin inhibited two steps in NF-κB signaling: TAK1TIKK and IKKTIκBα. Pristimerin potently inhibited two 
pairs of CML cell lines (KBM5 versus KBM5-T315I, 32D-Bcr-Abl versus 32D-Bcr-Abl-T315I) and primary cells from a CML 
patient with acquired resistance to imatinib. The mRNA and protein levels of Bcr-Abl in imatinib-sensitive (KBM5) or 
imatinib-resistant (KBM5-T315I) CML cells were reduced after pristimerin treatment. Further, inactivation of Bcr-Abl by 
imatinib pretreatment did not abrogate the TNFα-induced NF-κB activation while silencing p65 by siRNA did not affect 
the levels of Bcr-Abl, both results together indicating that NF-κB inactivation and Bcr-Abl inhibition may be parallel 
independent pathways.
Conclusion: To our knowledge, this is the first report to show that pristimerin is effective in vitro and in vivo against CML 
cells, including those with the T315I mutation. The mechanisms may involve inhibition of NF-κB and Bcr-Abl. We 
concluded that pristimerin could be a lead compound for further drug development to overcome imatinib resistance 
in CML patients.
Background
Chronic myelogenous leukemia (CML) is a myeloprolif-
erative disorder characterized by the presence of Bcr-Abl
which is formed by a reciprocal chromosomal transloca-
tion t(9,22)(q34;q11) [1,2]. Bcr-Abl is essential for malig-
nant transformation [3], and triggers several cellular
signaling pathways (e.g., CrkL, STAT5, PI3K/AKT) to
regulate cell proliferation, differentiation, migration, sur-
vival and DNA repair [4]. Targeting Bcr-Abl has therefore
been an important strategy for CML treatment [5]. Ima-
tinib (STI571, Gleevec, Norvartis) effectively inhibits
tyrosine kinase activity by occupying the adenosine
triphosphate (ATP)-binding pocket of Bcr-Abl, thus
abrogating subsequent signal transduction [6]. Of newly
diagnosed patients with chronic-phase CML, 82%
showed complete cytogenetic response on treatment with
imatinib over a median follow-up of 54 months [7]. How-
ever, resistance to imatinib develops over time and is an
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emerging problem for CML patients. Most cases of
acquired clinical resistance are due to mutations in the
kinase domain of Bcr-Abl. To overcome the acquired
resistance, second generation tyrosine kinase inhibitors
(e.g., nilotinib, dasatinib and INNO-406) have been
developed and are effective against all but the T315I
mutation which accounts for approximately 20% of
acquired resistance cases [8-11]. Hence, novel strategies
or com pounds t ha t can inhibit/kill CML c e lls carrying
Bcr-Abl-T315I are needed.
Abnormal constitutive NF-κB activation is widely
found in diverse types of hematopoietic malignancies
(e.g. CML [12], acute myeloid leukemia [13], Hodgkin's
disease [14]) as well as solid tumors. In particular, the
constitutive activation of NF-κB exists selectively in leu-
kemia stem cells but not in normal hematopoietic stem
cells [15]. Therefore, NF-κB may be a potential therapeu-
tic target for the selective eradication of leukemia stem
cells. CML blasts have constitutive p65 (RelA NF-κB)
transcriptional activity, and NF-κB may be a potential
target for molecular therapies in CML [16]. Indeed, phar-
macological inhibition of NF-κB was effective in killing
CML cells [17].
Pristimerin is a quinonemethide triterpenoid com-
pound isolated from Celastraceae and Hippocrateaceae.
Pristimerin has shown antimicrobial, anti-inflammatory,
antiperoxidation activities [18] as well as antitumor
effects in various types of human cancers [19-21].
Although pristimerin is known to be a potent inhibitor of
nuclear factor κB (NF-κB)-mediated transcription [20],
the detail mechanism by which pristimerin inhibits acti-
vation of NF-κB is unknown. In our continuing search for
effective compounds to kill CML cells carrying T315I-
Bcr-Abl [22,23], we tested this NF-κB inhibitor (pris-
timerin) against CML cells including those carrying
T315I-Bcr-Abl, and elaborated the mechanistic detail of
the inhibition of NF-κB by pristimerin. We extended our
work to translational studies evaluating the in vivo effi-
cacy of pristimerin against imatinib-resistant cells. We
also found that downregulating the levels of Bcr-Abl may
also be a relevant antineoplastic mechanism of pris-
timerin in malignant cells carrying Bcr-Abl.
Methods
Chemicals and antibodies
Pristimerin (Figure 1A, purity > 98%, HPLC) was
obtained from Paypaytech Inc. (Shenzhen, China). Pris-
timerin was dissolved in DMSO (Sigma, Shanghai) at a
stock concentration of 10 mM, and stored at -20°C. Ima-
tinib (STI571) was purchased from Alexis Biochemicals
(Plymouth Meeting, PA). Annexin V-FITC, and mouse
monoclonal antibody against actin were from Sigma-
Aldrich (Sigma, Shanghai). MG-132 was from Calbio-
chem (San Diego, CA). Recombinant human TNFα was
from Peprotech (Rocky Hill, NJ). Antibodies against p65,
IκBα, c-Abl (C-19), proliferating cell nuclear antigen
(PCNA), IKKα, cyclin D1 (C-20), apoptosis-inducing fac-
tor (AIF, H300), Bax, Bcl-XL, and Mcl-1 (S-19) were from
Santa Cruz Biotechnology (Santa Cruz, CA). Mouse anti-
bodies against poly(adenosine diphosphate [ADP]-
ribose) polymerase (PARP, clone 4C10-5), caspase-3, and
active caspase-3 (CM1), XIAP, cyclooxygenase-2 (Cox-2),
and cytochrome c (clone 6H2.B4) were from BD Biosci-
ences (San Jose, CA). Antibodies against phospho-IKKα
(Ser180)/IKKβ (Ser181), phospho-IκBα at Ser32, phos-
pho-p65 at Ser536, phospho-c-Abl at Y245, phospho-
Erk1/2 (T202/Y204), Erk1/2, phospho-AKT at Ser473
and AKT were from Cell Signaling Technology (Beverly,
MA). Antibodies against phospho-STAT5A/B (Y694/
Y699) (clone 8-5-2), STAT5A, and Bcl-2 were from
Upstate Technology (Lake Placid, NY). Anti-phospho-
RNA po lym e r ase  II ( S5)  was  fr om  Bet h yl La bo ra t ori es
(Montgomery, TX); Anti-survivin was from Novus Biol
(Littleton, CO). Anti-mouse immunoglobulin G and anti-
rabbit immunoglobulin G horseradish peroxidase-conju-
gated secondary antibodies were from Pierce Biotechnol-
ogy (Rockford, IL).
Cell culture
Imatinib-sensitive KBM5 cells bearing 210 kDa wild-type
Bcr-Abl, were grown in Iscove's modified Dulbecco's
medium (Invitrogen, Guangzhou, China) supplemented
with 10% heat-inactivated fetal calf serum (FCS), as
described previously [22,23]. Imatinib-resistant KBM5-
T315I cells bearing T315I mutation in Bcr-Abl were rou-
tinely maintained in the same medium but with 1.0 μM
imatinib, which was removed before experiments with a
wash-out period of 2-3 days. KBM5 and KBM5-T315I
had different sensitivities to imatinib; IC50 values were
0.28-0.53 and 5.04-5.40 μM, respectively [22,23]. The 32D
myeloid cells stably expressing either 210 kDa wild-type
Bcr-Abl (32D-Bcr-Abl) or T315I Bcr-Abl (32D-T315I)
were established and maintained in RPMI 1640 with 10%
FCS as described previously [23]. K562 cell was grown in
RPMI 1640 with 10% FCS. U2OS cells were cultured in
DMEM with 10% FCS. Cells in logarithmic phase were
used in all experiments starting with 2.0 × 105 cells/mL.
Primary cells from CML patients
Peripheral blood samples were obtained from 7 patients
with leukemia [5 CML, 1 JMML (juvenile myelomono-
cytic leukemia), 1 ALL (acute lymphoid leukemia), Addi-
tional file 1, Table S1] and 4 healthy adult donors in Sun
Yat-sen Memorial Hospital of Sun Yat-sen University, and
The First Affiliated Hospital of Sun Yat-sen University
after informed consent according to the institutional
guidelines and the Declaration of Helsinki principles.
Mononuclear cells were isolated by Histopaque gradientLu et al. Molecular Cancer 2010, 9:112
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centrifugation (density 1.077 g/mL; Sigma-Aldrich,
Shanghai, China). Contaminating red cells were lysed in
0.8% ammonium chloride solution for 10 minutes. After
washing with PBS, cells were suspended in RPMI 1640
supplemented with 10% FCS.
Luciferase assay
U2OS cells (2 × 105) were transfected with reporter plas-
mids encoding NF-κB-TATA-luc (60 ng) and pEFRenilla-
luc (10 ng) or together with plasmids encoding the
desired genes by use of LipofectAMINE 2000 (Invitro-
gen). After 24 hours, cells were left untreated or exposed
to pristimerin for 6 hours. The cell supernatants were
prepared immediately after stimulation with TNFα (0.1
nM), and luciferase activities were measured with use of
dual-luciferase assay kits (Promega, Madison, WI) as
described previously [24]. NF-κB activities were deter-
mined by normalization of NF-κB-dependent firefly
luciferase to Renilla luciferase activity. The pNF-κB-Luc
plasmid was from Stratagene (La Jolla, CA). The plasmids
Figure 1 Pristimerin abrogated TNF-induced NF-κB activation at TAK1 and IKK steps. (A) Structure of pristimerin. (B and C) Pristimerin inhibited 
TNFα-induced NF-κB-dependent reporter gene expression. U2OS cells were cotransfected with 60 ng NF-κB-TATA-Luc reporter plasmid and 10 ng 
Renilla luciferase reporter plasmid. 24 hours later, cells were treated with different concentrations of pristimerin (B) or a fixed concentration (200 nM) 
for various durations (C), then TNFα (0.1 nM) for 10 minutes; cell supernatants were prepared, and luciferase intensity was measured. The levels of firefly 
luciferase activity were normalized to Renilla luciferase activity. Results were expressed as fold change ± SE of at least 3 independent experiments. ***, 
P < 0.0001, one-way ANOVA, post hoc comparisons, Tukey's test. Columns, mean; error bars, SE. (D) Pristimerin abrogated IKK-induced NF-κB activation. 
U2OS cells were cotransfected with the indicated plasmids (p65, IKKα, IKKβ, IKKγ) along with NF-κB-TATA-Luc reporter plasmid. 24 hours later, cells 
were treated with 200 nM pristimerin for 6 hours. The expression of Renilla luciferase activity normalized transfection efficiency. *, P < 0.05; **, P < 0.01; 
***, P < 0.0001, one-way ANOVA, post hoc comparisons, Tukey's test. Columns, mean; error bars, SE. (E) Pristimerin diminished TAK1-induced NF-κB 
activation. U2OS cells were cotransfected with the TAK1-expressing plasmid and NF-κB-TATA-Luc reporter plasmid. 24 hours later, cells were treated 
with increasing concentrations of pristimerin for 6 hours. Luciferase activity was assayed as described above. **, P < 0.01; ***, P < 0.0001, one-way ANO-
VA, post hoc comparisons, Tukey's test. Columns, mean; error bars, SE.Lu et al. Molecular Cancer 2010, 9:112
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pCMV5-IKKα, pCMV5-IKKβ, pCMV5-IKKγ, pCMV5-
p65, and pCMV5-myc-TAK1 used for co-transfection
experiments were described previously [24].
Electrophoretic mobility shift assay (EMSA)
EMSA involved use of the LightShift Chemiluminescent
EMSA kit (Pierce Biotechnology, Shanghai) according to
the manufacturer's instructions [24]. The oligonucle-
otides for NF-κB were from Promega (Shanghai, China):
forward, 5-AGT TGA GGG GAC TTT CCC AGG C-3;
reverse, 5-G CCT GGG AAA GTC CCC TCA ACT-3.
The binding specificity was examined by competition
with a 200-fold excess of the unlabeled oligonucleotide
probe (cold competitor, Figure 2A, lanes 7 and 14).
Preparation of whole cell lysates and cytosolic fraction
Control or drug-treated cells were pelleted by centrifuga-
tion and rinsed with PBS. The whole lysates were then
prepared with RIPA buffer [22,25]. The cytosolic fraction
was prepared with digitonin extraction buffer to detect
the level of cytochrome c and AIF in the cytosol, as
described previously [22,25].
Preparation of cytoplasmic and nuclear fractions
TNFα- and/or pristimerin-treated cells were pelleted by
centrifugation and rinsed with PBS. Pellets were then
resuspended in 200 μl ice-cold lysis buffer (10 mM Hepes
pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.4% NP 40 with 1
mM DTT, 0.5 mM PMSF, 1 mM sodium orthovanadate
a nd C om pl et e Pr ot ease  Inhibit or  Mix)  by pipet t ing  up
and down (without bubbling) about 10 times [24,26].
After incubation on ice for 10 minutes, the lysates were
centrifuged at 10,000 g. The supernatants were trans-
ferred to fresh tubes and referred to as cytoplasmic
extracts. After washing with the lysis buffer, the pellets
were vigorously resuspended in nuclear protein extrac-
tion buffer with inhibitors (20 mM Hepes, pH 7.9, 0.4 M
NaCl, 1 mM EDTA with 1 mM DTT, 0.5 mM PMSF, 0.2
mM sodium orthovanadate and Complete Protease
Inhibitor Mix) and centrifuged for 10 minutes at 14,000 g
speed at 4°C. The resultant supernatants were kept as
nuclear fractions [24,26].
Immunofluorescence staining
After being preincubated with or without pristimerin for
6 hours, KBM5 cells were stimulated with TNFα. The
cells were harvested and cytospinned onto glass slides.
After fixation, and permeabilization, immunofluores-
cence staining was performed as described previously
[27].
Reverse transcription quantitative real-time PCR (RT-qPCR)
DNA-free total RNA was prepared with RNeasy mini-
columns, using the on-column DNAase digestion step
(Qiagen, Valencia, CA) and reverse transcribed into
cDNA following the instruction of Invitrogen Super-
Script III First-Stand Kit. Quantitative real-time PCR was
performed with Roche LightCycler 480 according to the
manufacture's recommended protocol. Optimal reaction
conditions for amplification of both Bcr-Abl and 18S
were as follows: 40 cycles of a two-step PCR (95°C for 15
s, 60°C for 20 s) after initial denaturation (95°C for 30s)
with 5 μl of cDNA reaction by TaKaRa SYBR Premix Ex
Taq Kit. The PCR-primers was as follow: Bcr-Abl - sense:
5'-TCCACTCAGCCACTGGATTTAA-3', antisense:
5'-TGAGGCTCAAAGTCAGATGCTACT-3'; Sirt1 -
sense:
5'-GAGTGGCAAAGGAGCAGATT-3', antisense:
5'-ATGTAACGATTTGGTGGCAA-3'; 18S - sense:
5'-AAACGGCTACCACATCCAAG-3', antisense:
5'-CCTCCAATGGATCCTCGTTA-3'. The mRNA
expression of Bcr-Abl or Sirt1 was normalized as
described previously [28]. The results of three indepen-
dent experiments are reported.
Small interfering RNA transfection
Small interfering RNA (siRNA) duplexes against p65
were from Cell Signaling Technology (Beverly, MA); ON-
TARGETplus SMARTpoolsiRNA duplexes against
human PDGFRa or ON-TARGETplus Non-Targeting
Pool siRNA control were from Dharmacon RNA Tech.
(Lafayette, CO) [27]. Transfection of either anti-p65,
PDGFRα or the control synthesized siRNA duplexes into
K562 cells was performed with the Cell Line Nucleofector
Kit T (Amaxa, Gaithersburg, MD) and program O-17
according to the manufacturer's instruction [27]. Twenty-
four hours after siRNA transfection, the cells were ana-
lyzed with Western blotting.
Cell viability assay
Cell viability was determined by MTS assay (CellTiter 96
Aqueous One Solution Cell Proliferation assay; Promega,
Madison, WI) [22,24]. An amount of 100 μl cells (2.0 ×
105/mL) were seeded in 96-well plates and incubated with
various concentrations of pristimerin for 72 hours. Four
hours before culture termination, 20 μL of MTS solution
was added to each well. Absorbance was read on a 96-
well plate reader at a wavelength of 490 nm. Control cells
received DMSO (< 0.1%) containing medium. The drug
concentration resulting in 50% inhibition of cell growth
(IC50) was determined.
Soft agar clonogenic assay
To evaluate anchorage-independent growth of tumor
cells, CML cells (2 × 105/ml) were treated with increasing
concentrations of pristimerin or diluent (DMSO, control)
for 24 hours, then washed with PBS; the same amounts of
viable cells (as determined by trypan blue exclusion assay
and a hemocytometer) were subsequently seeded in 6-Lu et al. Molecular Cancer 2010, 9:112
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well plates in Iscove's medium containing 0.3% agar and
20% FCS in the absence of drug treatment. After incuba-
tion for 10 ￿ 14 days at 37°C, colonies composed of more
than 50 cells were counted using an inverted phase-con-
trast microscope, as described previously [22,24].
Tumor xenograft experiments
Male nu/nu BALB/c mice were bred at the animal facility
of Sun Yat-sen University. The mice were housed in bar-
rier facilities with a 12-h light dark cycle, with food and
water available ad libitum. 3 × 107 of KBM5-T315I cells
were inoculated subcutaneously on the flanks of 4- to 6-
week-old male nude mice. Tumors were measured every
other day with use of calipers. Tumor volumes were cal-
culated by the following formula: a2 × b × 0.4, where a is
the smallest diameter and b is the diameter perpendicular
to a. Pristimerin was dissolved in DMSO and diluted with
vehicle [30% Cremophor EL/ethanol (4:1), 70% PBS].
Mice in the control group received the same amount of
vehicle treatment. The body weight, feeding behavior and
motor activity of each animal were monitored as indica-
tors of general health. The animals were then euthanized,
Figure 2 Pristimerin inhibited DNA binding of NF-κB to DNA. (A) KBM5 cells were preincubated in the absence or presence of 200 nM pristimerin 
for 6 hours; TNFα was added at different times, and the nuclear extracts were then assayed for NF-κB activation by EMSA. Cold competitor: the labeled 
NF-κB oligonuceotide was competed with an excess (200 fold) of unlabeled probe. (B) KBM5 cells were pretreated with or without escalating concen-
trations of pristimerin for 6 hours; TNFα (0.1 nM) was added for 30 minutes. EMSA was used to detect the activation of NF-κB. Results are representative 
of 3 independent experiments. (C) Pristimerin did not directly interfere with NF-κB complex formation. Nuclear extracts from KBM5 cells treated with 
or without 0.1 nM TNFα for 30 minutes, were reacted in the absence or presence of increasing concentrations of pristimerin, then NF-κB activation 
was assayed by EMSA.Lu et al. Molecular Cancer 2010, 9:112
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and tumor xenografts were immediately removed,
weighed, stored and fixed. All animal studies were con-
ducted with the approval of the Sun Yat-sen University
Institutional Animal Care and Use Committee.
Immunohistochemical staining
Formalin-fixed xenografts were embedded in paraffin
and sectioned according to standard techniques. Tumor
xenograft sections (4 μm) were immunostained using the
MaxVision kit (Maixin Biol, Fuzhou, China) according to
the manufacturer's instructions [22,23].
Flow cytometry analysis
Cell cycle analysis
Cells treated and control were harvested, washed with
PBS, and fixed with 66% ethanol over night. Cells were
centrifuged and washed with PBS, then stained with 50
μg/mL propidium iodide and 2.5 μg/mL RNase in PBS
solution for 30 minutes at room temperature. DNA con-
tent was analyzed by flow cytometry at the emission
wavelength of 488 nm [22].
Apoptosis measurement
Apoptosis was measured by flow cytometry using
Annexin V/Propidium iodide (PI) double staining. Cells
were cultured in the presence of indicated concentrations
of pristimerin for 24 hours, harvested and washed, and
incubated in binding buffer (Annexin V Binding Buffer,
BD Pharmingen) with 0.3% Annexin V-FITC for 15 min-
utes at room temperature. The cells were washed and
resupended in binding buffer. Propidium iodide was
added just before flow cytometric analysis [22,24].
Statistical analysis
GraphPad Prism 4.0 software (GraphPad Software, San
Diego, CA) was used for statistical analysis. Comparisons
between 2 groups involved two-sided Student's t test, and
comparisons among multiple groups involved one-way
ANOVA with post-hoc intergroup comparisons using
Tukey test. P < 0.05 was considered statistically signifi-
cant.
Results
Pristimerin inhibits TNF-induced NF-κB-dependent 
reporter gene transcription
We first examined whether pristimerin affected the
TNFα-induced NF-κB-dependent reporter gene tran-
scription. One day after cotransfection with pNF-κB-
TATA-Luc and pEFRRenilla-Luc, U2OS cells were
exposed to pristimerin at increasing concentrations for 6
hours or a fixed concentration (200 nM) for different
durations. Prior to the termination of culture, TNFα was
added for 10 minutes. The luciferase activity detected
was increased by TNFα (Figure 1B); but pristimerin
inhibited the TNFα-induced NF-κB reporter activity in a
dose- and time-dependent manner (Figure 1B and 1C).
Pristimerin inhibits NF-κB activation induced by p65, IKKα, 
IKKβ, IKKγ and TAK1
In the canonical NF-κB activation pathway, TAK1 and
IKK are the major upstream regulators of IκBα. To deter-
mine the steps at which pristimerin acted, U2OS cells
were cotransfected with plasmids to express IKKα, IKKβ
or IKKγ, along with an NF-κB-TATA-Luc reporter plas-
mid. The luciferase activity of NF-κB-TATA-Luc reporter
was significantly increased when cotransfected with p65,
IKKα, IKKβ, or IKKγ constructs (Figure 1D) compared
with transfection with reporter alone. However, addition
of pristimerin significantly inhibited the NF-κB tran-
scriptional activity (Figure 1D). Therefore, pristimerin
could block NF-κB activation induced by IKK overex-
pression.
Because TAK1 is critical upstream regulator of IKK
[29], we assessed the effect of pristimerin on cotransfec-
tion of a TAK1 construct along with NF-κB-TATA-Luc
reporter plasmid. TAK1 significantly elevated NF-κB
reporter luciferase activity (Figure 1E), and pristimerin
significantly blocked TAK1-induced NF-κB activation.
Pristimerin inhibits DNA binding of NF-κB in intact cells but 
does not directly interfere with binding of NF-κB to DNA in 
a purified nuclear extract
We next examined whether pristimerin interfered with
the binding of NF-κB to DNA by EMSA. KBM5 cells were
preincubated with or without 200 nM pristimerin for 6
hours; TNFα was added for the indicated times, then
nuclear extracts were assayed for NF-κB DNA binding
activity by EMSA with a probe representing an NF-κB-
binding site. After stimulation with TNFα, the levels of
the NF-κB-DNA complex were steadily increased over
time in the absence of pristimerin (Figure 2A, lanes 2-5
versus lane 1). With the same durations of stimulation
with TNFα, NF-κB-DNA complex were not formed in the
presence of 200 nM pristimerin (Figure 2A, lanes 8-12).
Competition with an excess (200-fold) of unlabeled probe
led to disappearance of the TNFα-induced bound com-
plex (Figure 2A, lanes 7 and 14), which confirmed the
binding specificity of this assay. Pretreatment for 6 hours
with increasing concentrations of pristimerin abrogated
TNFα-induced NF-κB-DNA complex formation in a
dose-dependent manner (Figure 2B).
To address whether pristimerin exerted a direct inhibi-
t o ry  e f f e c t  o n  t h e  b i n d i n g  o f  N F - κ B  t o  D N A,  n u c l e a r
e x t r a c t s  p r e p a r e d  f r o m  u n t r e a t e d  K B M 5  c e l l s  o r  c e l l s
stimulated with TNFα were incubated in a cell-free reac-
tion system in the presence of increasing concentrations
of pristimerin. Pristimerin, even at a concentration as
high as 20 μM, did not block the TNFα-induced forma-
tion of NF-κB-DNA complex (Figure 2C), suggesting that
pristimerin did not directly interfere with binding of NF-
κB to DNA in a purified nuclear extract.Lu et al. Molecular Cancer 2010, 9:112
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Pristimerin inhibits TNFα-induced degradation of IκBα and 
translocation of p65
The findings that pristimerin inhibited TNFα-induced
NF-κB transcriptional function and formation of an NF-
κB-DNA binding complex predicted that pristimerin
would affect IκBα phosphorylation and p65 transloca-
tion. To test this hypothesis, KBM5 or KBM5-T315I were
pretreated with 200 nM pristimerin for 6 hours, then
stimulated with TNFα; cytoplasmic and nuclear extracts
were examined by Western blot analysis with antibodies
against total and phosphorylated forms of TAK1, IKKα/β,
IκBα and p65, respectively. In the absence of pristimerin
(Figure 3A, left, control), the levels of phosphorylated
TAK1 and phosphorylated IKKα/β in the cytoplasmic
fraction of KBM5 cells were appreciably increased start-
ing at 5 minutes after TNFα stimulation as compared
with untreated cells. The levels of phosphorylated IκBα
appeared as a pulse signal that peaked at 5 minutes after
TNFα stimulation and then decreased back to baseline
(Figure 3A) as previously reported by Anand et al. [30].
Subsequently (starting 5 minutes after TNFα stimula-
tion), the levels of total IκBα protein in the cytoplasmic
fractions decreased, which was consistent with activation
of ubiquitination and proteasomal degradation triggered
by the phosphorylation of IκBα [31]. In contrast, pris-
timerin completely abolished the phosphorylation of
IKKα/β and IκBα induced by TNFα (Figure 3A, left, pris-
timerin). Accordingly, the TNFα-induced IκBα degrada-
tion was abrogated by pristimerin. The levels of
phosphorylated and total p65 in the nuclear fractions
were increased in TNFα-stimulated cells (Figure 3B, left,
control). The increase in nuclear p65 was markedly abro-
gated by the pristimerin (Figure 3B, left, pristimerin).
Similar findings were obtained in KBM5-T315I cells (Fig-
ure 3A and 3B, right panels). Further, pristimerin time-
and dose-dependently abrogated the TNFα-induced IκBα
degradation and p65 translocation (Figure 3C). The
inhibitory effect of pristimerin on TNFα-induced translo-
cation of p65 was further confirmed by immunofluores-
cent microscopy (Figure 3D).
Pristimerin inhibits TNFα-dependent IκBα phosphorylation
Because IαBκ phosphorylation is a critical step to tag the
protein and trigger ubiquitination-proteosome-depen-
dent degradation of IκBα [32], we next examined whether
pristimerin inhibited the degradation of IκBα via inhibit-
ing IκBα phosphorylation. TNFα stimulation elevated the
levels of phosphorylated IκBα in KBM5 cells (Figure 3E),
which was potentiated by the presence of the proteosome
inhibitor MG-132. However, pristimerin completely
blocked the TNFα-induced phosphorylation of IκBα even
in the presence of MG-132.
Pristimerin prevents TNFα from inducing NF-κB-dependent 
gene products involved in survival and apoptosis
It is believed that the pro-survival function of NF-κB is
mediated through NF-κB-regulated expression of cell
survival proteins whose genes containing an NF-κB bind-
ing site in their promoters (e.g., Bcl-XL, survivin, Mcl-1,
cyclin D1, c-myc, Bcl-2, and Cox 2) [30]. Because pris-
timerin inhibits TNFα-induced activation of NF-κB, we
hypothesized that it would also inhibit TNFα-induced
expression of cell survival proteins. K562 cells were
treated with or without 400 nM pristimerin for 6 hours,
followed by stimulation with TNFα for up to 24 hours.
The levels of Bcl-XL, survivin, Mcl-1, cyclin D1, c-myc,
Bcl-2, and Cox 2 as detected by immunoblotting were
increased after TNFα stimulation (Figure 3F), and the
TNFα-induced upregulation of these genes was abolished
by pristimerin (Figure 3F).
Pristimerin decreases Bcr-Abl mRNA and inactivates its 
downstream signaling
We also examined the effect of pristimerin on the expres-
sion of Bcr-Abl in CML cells by immunoblotting.
Twenty-four-hour treatment with pristimerin dose- and
time-dependently decreased levels of Bcr-Abl protein in
KBM5, KBM5-T315I or K562 cells (Figure 4A). Bcr-Abl
can activate multiple signal transduction pathways (e.g.,
CrkL, STAT5, Erk1/2, and PI3K/AKT) which can pro-
mote cell proliferation and resistance to apoptosis [3]. We
reasoned that the loss of total Bcr-Abl protein would lead
to a decrease in its kinase activity. We measured auto-
phosphorylation by immunoblotting with the phospho-
specific antibody against the phosphorylated Y245 c-Abl
as described previously [33]. Basal phosphorylation of
Bcr-Abl was detectable in KBM5, KBM5-T315I and K562
cells (Figure 4A). As expected, pritstimerin potently
decreased the amount of phosphorylated Bcr-Abl in
accord with decrease in the total Bcr-Abl protein (Figure
4A). To better define the effect of pristimerin on Bcr-Abl
signaling, we followed the phosphorylation of Bcr-Abl
and its downstream targets over time. The levels of Bcr-
Abl and phosphorylated Bcr-Abl started to decrease as
early as 3 hours after pristimerin treatment, and contin-
ued to decrease up to 24 hours after pristimerin treat-
ment (Figure 4B). Concomitantly, the phosphorylation of
CrkL, STAT5, Erk1/2 and AKT decreased (Figure 4B).
The total protein levels of STAT5 and AKT did decrease
at later time points. Taken together, pristimerin
decreased Bcr-Abl and inhibited its downstream signal-
ing. Notably, the decrease in Bcr-Abl protein levels pre-
ceded the onset of apoptosis, as indicated by specific
PARP cleavage and caspase-3 activation after pristimerin
treatment (Figure 4C).
To investigate whether the proteosome pathway was
involved in the pristimerin-mediated downregulation ofLu et al. Molecular Cancer 2010, 9:112
http://www.molecular-cancer.com/content/9/1/112
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Figure 3 Pristimerin inhibits TNFα-induced degradation of IκBα and translocation of p65. KBM5 or KBM5-T315I cells were pretreated with or 
without 200 nM pristimerin for 6 hours, then treated with TNFα (0.1 nM) at the indicated times; cytoplasmic (A) and nuclear (B) extracts were examined 
by Western blot analysis with specific antibodies against total and phosphorylated IκBα, IKK and p65, respectively. The same membranes were stripped 
and reprobed with actin or PCNA. (C) Dose- and time-dependent effect of pristimerin. KBM5 cells were preincubated with the indicated concentra-
tions of pristimerin for 6 hours (left) or 200 nM pristimerin for various durations (right); then treated with TNFα (1 nM) for 5 minutes; cytoplasmic and 
nuclear extracts were examined by Western blot analysis. (D) Immunofluorescence staining analysis of p65. KBM5 cells were preincubated with 200 
nM pristimerin for 6 hours, and TNFα (1 nM) for 5 minutes, fixed in 3% paraformaldehyde, then underwent immunofluorescence analysis against p65 
and FITC-conjugated secondary antibody. Nuclei were stained with 4,6-diamidino-2-phenylindole (DAPI). (E) Pristimerin prevented the phosphoryla-
tion of IκBα in the presence of proteosome inhibitor. KBM5 cells were treated with 500 nM pristimerin in the absence or presence of MG-132 (0.5 μM) 
for 6 hours, then treated with TNFα (0.1 nM) for 30 minutes. Cytoplasmic extracts of cells underwent immunoblotting with phosphopecific anti-IκBα. 
(F) Pristimerin diminishes the expression of NF-κB-regulated proteins involved in survival. Western blot analysis of K562 cells pretreated with 400 nM 
pristimerin for 6 hours, then stimulated with TNFα (1 nM) for different times.Lu et al. Molecular Cancer 2010, 9:112
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Figure 4 Decreasing Bcr-Abl and its downstream signaling, and inhibiting NF-κB may be independent mechanisms of actions of pristimer-
in. (A) Dose-dependent downregulation of Bcr-Abl protein by pristimerin. CML cells were exposed to pristimerin for 24 hours, whole cell lysates were 
subjected to immunoblotting analysis. (B and C) CML cells were treated with 600 nM pristimerin for different durations, downstream signaling mole-
cules of Bcr-Abl (B) and proteins of apoptosis (C) were analyzed by Western blotting. (D) K562 cells were pretreated with MG-132 (0.5 μM) for 2 hours, 
then exposed to pristimerin for another 24 hours. Immunoblots were shown. (E) Pristimerin inhibits Bcr-Abl mRNA levels as measured by RT-qPCR. 
KBM5 cells were exposed to escalating concentrations of pristimerin for 24 hours (left top and middle) or 600 nM for various durations (right top and 
middle). The Bcr-Abl mRNA expression relative to the control was calculated by dividing the comparative expression levels. Colomns, mean;bars, 95% 
confidence intervals, n = 3. Similar data for Sirt1 (an unrelated control gene) were also shown (bottom). **, P < 0.01; ***, P < 0.0001, one-way ANOVA, 
post-hoc comparisons, Tukey's test. (F) KBM5 cells were pretreated with 1.0-3.0 μM imatinib for 1 hour, the cells were then stimulated with TNFα (0.1 
nM, 5 minutes), NF-κB activation was analyzed with Western blotting. (G) K562 cells were transfected with siRNA duplexes against either human p65, 
PDGFRα or control siRNA, respectively. Twenty-four hours later, the cells were analyzed by Western blotting. (H) A proposed model to delineate the 
actions of pristimerin.Lu et al. Molecular Cancer 2010, 9:112
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Bcr-Abl, we pretreated K562 cells with a sub-cytotoxic
concentration (0.5 μM) of the proteosome inhibitor MG-
132, but found no effect on the decrease in Bcr-Abl pro-
tein levels (Figure 4D). Similarly, the pristimerin-induced
decrease of Bcr-Abl protein was not rescued by the pres-
ence of caspase-3 inhibitor z-DEVD-fmk (data not
shown).
We next examined whether pristimerin inhibited Bcr-
Abl at the transcriptional levels. KBM5 and KBM5-T315I
cells were exposed to various concentrations of pris-
timerin for 24 hours (left) or 600 nM for different dura-
tions (right); reverse transcription quantitative real-time
PCR (RT-qPCR) revealed that the mRNA levels of Bcr-
Abl were decreased after treatment with pristimerin (Fig-
ure 4E) while the mRNA levels of Sirt1 gene (an unrelated
gene control) were not decreased, suggesting a selective
activity of pristimerin against Bcr-Abl transcription.
The possibility of interdependence of the two actions of
pristimerin (i.e., NF-κB inactivation and depletion of Bcr-
Abl) was tested. First, we examined whether the TNFα-
induced NF-κB activation was dependent on Bcr-Abl. We
pretreated KBM5 cells with 1.0-3.0 μM imatinib for 1
hour to inactivate Bcr-Abl, the cells were then stimulated
with TNFα (0.1 nM, 5 minutes), followed by analysis of
NF-κB activation. Imatinib treatment led to dephospho-
rylation of Bcr-Abl, which, however, did not abrogate the
TNFα-induced IκBα phosphorylation, and subsequent
relocation of p65 (Figure 4F). Second, we employed the
siRNA approach to determine the effect of p65 on Bcr-
Abl in CML cells. The levels of p65 were appreciably
decreased in K562 cells 24 hours after transfection with
siRNA duplexes specifically against p65 when compared
with control siRNA and PDGFRα siRNA (unrelated gene
control) (Figure 4G). Silencing p65 did not affect the lev-
els of Bcr-Abl. The above results together implicate that
NF-κB inactivation and Bcr-Abl inhibition may be paral-
lel independent pathways.
Pristimerin inhibits growth of imatinib-sensitive and 
imatinib-resistant CML cells
We then evaluated the effect of pristimerin on the growth
of CML cells. Human CML cell lines (KBM5, KBM5-
T315I and K562), and a pair of murine myeloid cells 32D
stably transfected with either the wild-type or T315I
human Bcr-Abl were exposed to escalating concentra-
tions of pristimerin for 72 h, followed by the MTS assay.
Cell viability of all 5 lines of CML cells was inhibited, with
IC50 values of 199 nM, 135 nM, 450 nM, 242 nM and 387
nM, respectively (Figure 5A). These data suggest similar
sensitivities of imatinib-sensitive and imatinib-resistant
CML cells to pristimerin.
Because clonogenicity is believed to better reflect
m a l i g n a n t  b e h a v i o r  o f  t u m o r  c e l l s ,  w e  c o m p a r e d  t h e
impact of pristimerin on clonogenicity in CML cells with
that of imatinib. We examined the clonogenicity of KBM5
and KBM-T315I cells after a 24 hour-treatment of ima-
tinib. The IC50 values of KBM5 and KBM5-T315I to ima-
tinib were 0.45 μM and 4.10 μM, respectively (data for
dose-response curves not shown). The results confirmed
the resistance of KBM5-T315I cells to imatinib. In con-
trast, pristimerin treatment potently inhibited the num-
ber of surviving clonogenic KBM5, KBM5-T315I and
K562 cells in a dose-dependent manner, with IC50 values
of 43.7 nM, 35.9 nM and 36.5 nM, respectively (Figure
5B).
Primary leukemia cells from imatinib-resistant CML patient 
are also sensitive to pristimerin
We next ascertained the activity of pristimerin against
imatinib-resistant primary CML cells. Mononuclear cells
in peripheral blood from 1 CML patient who acquired
clinical resistance to imatinib versus 4 CML patients that
responded to imatinib were exposed to various concen-
trations of pristimerin for 72 hours. The primary CML
cells were sensitive to pristimerin as well, with IC50values
6-578 nM (Table 1). In particular, the primary leukemia
cells from 1 CML patient with acquired clinical resistance
to imatinib were also sensitive to pristimerin (IC50value
578 nM). Of interest, primary leukemia cells from 1
patient with JMML (juvenile myelomonocytic leukemia)
and 1 patient from ALL (acute lymphoid leukemia) were
also sensitive to pristimerin (Table 1).
We also examined the effect of pristimerin on normal
bone marrow cells. Normal bone marrow cells collected
from 4 healthy donors were treated with increasing con-
centrations of pristimerin for 72 h; cell viability assayed
by MTS indicated that pristimerin was cytotoxic to nor-
mal bone marrow cells with a median IC50 value of 740.5
nM (range, 681-999 nM). These data were in line with the
report by Costa et al. [19] who showed that pristimerin
inhibited the cell viability of peripheral blood mononu-
clear cells with an IC50 value of 880 nM. Therefore, bone
marrow suppression may be a significant side effect of
pristimerin.
Pristimerin inhibits the growth of xenografted KBM5-T315I 
cells in nude mice
We next evaluated the in vivo activity of pristimerin
against imatinib-resistant CML cells using the nude
mouse xenograft model. Twenty six nu/nu BALB/c mice
were injected with KBM5-T315I cells. Five days after
inoculation of tumor cells, when the size of tumor
reached approximately 50 mm3, mice inoculated with
KBM5-T315I cells were randomized to receive intratu-
moral injection with either 50 μL vehicle [30% Cremo-
phor EL/ethanol (4:1), 70% PBS] or 1.0 mg/kg pristimerin
in vehicle daily during days 6-19 after inoculation ofLu et al. Molecular Cancer 2010, 9:112
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Figure 5 Pristimerin inhibits growth of imatinib-resistant CML cells in vitro and in vivo. (A) The indicated 5 lines of CML cells were exposed to 
escalating concentrations of pristimerin for 72 hours, cell viability was measured by MTS assay. (B) Clonogenicity of CML cells in soft agar was inhibited 
by pristimerin in a dose-dependent manner. Error bars represent SE. (C, D, E) Pristimerin inhibited the growth of xenografted imatinib-resistant CML 
cells in a nude mouse model. (C) The growth curves of subcutaneous xenografts of KBM5-T315I cells. Nude mice bearing KBM5-T315I xenograft tu-
mors received intratumoral injection with either 50 μL vehicle [30% Cremophor EL/ethanol (4:1), 70% PBS] or 1.0 mg/kg pristimerin in vehicle daily 
during days 6-19 after inoculation of KBM5-T315I cells. The estimated tumor volume is plotted versus time (C). Points, mean; Error bars, SE. (D) Weights 
of tumors dissected on day 19 post-inoculation. Columns, mean; error bars, SE. *** indicates P < 0.0001, Student's t test. Representative tumors re-
moved from mice of each group. (E) Immnunohistochemical analysis with anti-c-Abl and H & E staining of xenograft tissues from mice sacrificed 19 
days after tumor inoculation.Lu et al. Molecular Cancer 2010, 9:112
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KBM5-T315I cells. The growth curves (the estimated
tumor size calculated from the tumor dimension versus
time) are shown in Figure 5C. Pristimerin potently inhib-
ited the growth of KBM5-T315I tumors. The weight of
tumors was significantly lower in the treated group than
in the control (vehicle) group (Figure 5D, P < 0.0001).
Immnunohistochemical analysis with an anti-c-Abl anti-
body (to detect both c-Abl and Bcr-Abl) revealed that c-
Abl immunoreactivity was markedly decreased by pris-
timerin treatment (Figure 5E). These data again pointed
to the antitumor activity of pristimerin.
Pristimerin does not affect cell cycling
After exposing CML cells to various concentrations of
pristimerin for 24 hours, cell cycle analysis was con-
ducted by using flow cytometry with propidium iodide
staining. The results revealed no significant cell cycle
alteration in CML cells treated with various concentra-
tions of pristimerin for 24 hours except for the appear-
ance of the sub-G1 apoptotic population (Figure 6).
Pristimerin induced apoptosis in imatinib-sensitive and 
imatinib-resistant CML cells
The ability for pristimerin to induce apoptosis in CML
cells was assessed by flow cytometry after staining with
Annexin V and propidium iodide. After treatment with
pristimerin apoptosis was induced in a dose- and time-
dependent manner (Figure 7A, 7B) in the CML cells. In
parallel, Western blotting analysis revealed that pris-
timerin induced a dose-dependent specific cleavage of
PARP, which is a hallmark of apoptosis (Figure 7C). Con-
comitantly, pristimerin led to a decline of the precursor
form of caspase-3, reflecting its activation.
Most chemotherapeutic agents induced apoptosis by
triggering release of cytochrome c and AIF from mito-
chondria into the cytosol. To evaluate the apoptosis path-
way activated by pristimerin, CML cells were exposed to
pristimerin, cytochrome c and AIF in the cytosolic frac-
tion was examined by Western blotting at different time
points. Cytochrome c and AIF were undetectable in the
cytosol of control cells, but were released from the mito-
chondria into the cytosol after pristimerin treatment
(Figure 7D). The results implied that pristimerin trig-
gered the mitochondrial pathway of apoptosis. Pris-
timerin activated the same apoptotic pathway in breast
cancer cells as reported by Wu C et al. [21] The effect of
pristimerin on antiapoptotic proteins (Bcl-2, Bcl-XL, Mcl-
1, survivin) of the Bcl-2 gene family regulating the mito-
chondrial pathway of apoptosis was also examined. Pris-
timerin treatment decreased the levels of Bcl-XL and Mcl-
1 in a dose- and time-dependent manner without affect-
ing Bcl-2, XIAP, Bax and survivin (Figure 7E and 7F).
Discussion
The prognosis of CML resistant to imatinib is poor [8].
Bcr-Abl-T315I mutation is a major cause to confer resis-
tance to STI571 as well as the second generation of
tyrosine kinase inhibitors. NF-κB may represent an
important mechanism to prevent apoptosis in tumor
cells. In the present study, we discovered that pristimerin
potently blocked NF-κB signaling and dramatically
downregulated Bcr-Abl mRNA regardless of the muta-
tional status of Bcr-Abl, inhibited growth and induced
apoptosis in CML cells harboring wild-type Bcr-Abl or
Bcr-Abl-T315I mutation. We confirmed this activity with
two pairs of CML cell lines (KBM5 versus KBM5-T315I,
32D-Bcr-Abl versus 32D-Bcr-Abl-T315I) and primary
cells from CML patients. Additionally, pristimerin inhib-
ited the growth of imatinib-resistant Bcr-Abl-T315I in
nude mouse xenografts. To our knowledge, this is the first
report to show that pristimerin is effective in vitro and in
vivo against CML cells, including those with the T315I
mutation. Because none of the currently available
tyrosine kinase inhibitors in clinical use are effective
against CML cells bearing T315I-Bcr-Abl, our findings
are of particular interest.
Table 1: IC50 values of primary leukemia cells from patients with leukemia to pristimerin.
Patient no. Diagnosis Imatinib sensitive Imatinib resistance IC50 (nM)
1C M L × 5 7 8
2C M L × 6 . 2 8
3C M L × 3 2 6
4C M L × 1 8 6
5C M L × 2 1 0
6J M M L 326
7A L L 205
Note: CML, chronic myelogeneous leukemia; JMML, juvenile myelomonocytic leukemia; ALL, acute lymphoid leukemia.Lu et al. Molecular Cancer 2010, 9:112
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Inhibition of proteasomes was reported as a mecha-
nism by which pristimerin induces apoptosis in prostate
cancer cells [34]. However, inhibition of proteasome
occurs at micromolar concentrations (pristimerin at 2.2-
3.0 μM inhibited 50% of the proteolytic activity of puri-
fied 20S proteasome; pristimerin at 5.0 μM inhibited pro-
teasomal activity by 30%-40% in tumor cells [34]) while
the inhibition of Bcr-Abl transcription and inactivation of
NF-κB signaling occur in nanomolar concentrations (Fig-
ures 3 and 4). Moreover, no increased cell death in CML
cells was observed when pristimerin was combined with
MG-132 (a proteasome inhibitor). Therefore, inhibition
of proteasomes is unlikely to be a relevant mechanism by
which pristimerin induces apoptosis in CML cells.
The inhibitory action of pristimerin against NF-κB has
been documented in murine macrophages (RAW 264.7)
induced by lipopolysaccharide [18] and in human
myeloma cells induced by TNFα [20]. In these previous
reports, only NF-κB-dependent reporter gene assay and
EMSA data were reported; the precise steps in NF-κB sig-
naling that were inhibited by pristimerin were not ascer-
tained. In this study, we thoroughly examined the effect
of pristimerin on NF-κB signaling beyond NF-κB-depen-
dent gene reporter and DNA binding of NF-κB (EMSA)
to include IκBα phosphorylation, translocation of p65,
and expression of NF-κB-regulated genes. We pinpointed
the precise steps at which pristimerin exerted its inhibi-
tory action in the signaling cascade of NF-κB: TAK1TIKK
and IKKTIκBα (Figure 3A; Model in Figure 4H).
Oncogenic mutations such as Bcr-Abl, PDGFRα, KIT,
and Ras have been demonstrated to lead to constitutive
activation of NF-κB [16], [35-38]. Reuther et al. demon-
strated that NF-κB activation was essential for Bcr-Abl-
induced transformation [37]. Inactivation of Bcr-Abl, Flt3
and PDGFRα by specific inhibitors can ablate the NF-κB
activation [12]. By this potential mechanism, rapid
decrease of Bcr-Abl by pristimerin may cause or enhance
inactivation of NF-κB signaling. Despite the fact that Bcr-
Abl kinase is sufficient to elicit constitutive activation of
NF-κB, NF-κB activation may also occur via an oncogenic
mutations-independent mechanism. For instance, inhibi-
tion of Flt3 by its inhibitor AG1296 in primary AML blast
cells variably affected constitutive NF-κB activation, indi-
cating that a Flt3-independent mechanism of NF-κB acti-
vation existed [35,39]. Additionally, cytokines including
TNFα are increased in the serum of patients with CML
Figure 6 Effect of pristimerin on cell cycling in CML cells. KBM5, KBM5-T315I or K562 cells were treated with pristimerin at the indicated concen-
trations for 24 hours, cell cycling was analyzed by flow cytometry after staining with propidium iodide. Graphs show data from a representative ex-
periment.Lu et al. Molecular Cancer 2010, 9:112
http://www.molecular-cancer.com/content/9/1/112
Page 14 of 17
Figure 7 Pristimerin induces apoptosis in imatinib-sensitive and -resistant CML cells by eliciting mitochondrial damage. (A, B, C) CML cells 
were exposed to pristimerin with concentrations ranging from 0 to 600 nM for 24 hours (A), or 600 nM pristimerin for various durations (B), then the 
cells underwent Annexin V/PI double staining for apoptotic cell death assay. Parallel samples were lysed for immunoblotting analysis with antibody 
against caspase-3 and PARP (C). (D) Pristimerin induced mitochondrial release of cytochrome c and apoptosis-inducing factor (AIF). KBM5, KBM5-T315I 
or K562 cells were treated with pristimerin at 600 nM, 600 nM and 800 nM, respectively, for 0-24 hours; levels of cytochrome c in the cytosolic extracts 
prepared using a digitonin buffer were detected by Western blot analysis. (E) Western blot analysis of apoptosis-related proteins such as Bcl-2, Bcl-XL, 
Mcl-1 and survivin was shown. The indicated CML cells were exposed to pristimerin for 24 h. (F) Immunoblotting analysis of apoptosis-related proteins 
in response to pristimerin (600 nM) for different durations was shown.Lu et al. Molecular Cancer 2010, 9:112
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compared with healthy individuals [40]. The abnormal
microenvironment in CML bone marrow likely causes
deregulated secretion of cytokines by stromal cells [41].
Of note, our data revealed that inactivation of Bcr-Abl by
imatinib did not interfere with the TNFα-induced NF-κB
activation as reflected by IκBα phosphorylation and sub-
sequent relocation of p65. Moreover, silencing p65 did
not affect the levels of Bcr-Abl. Together, our results
implicate that NF-κB inactivation and Bcr-Abl inhibition
may be parallel pathways for pristimerin actions. Future
work should assess the relative importance of these two
mechanisms.
Pristimerin decreased mRNA of Bcr-Abl. Our data did
not support that pristimerin is a global transcription
inhibitor (e.g. triptolide [42] and flavopiridol [33]),
because pristimerin treatment did not affect the activity
of RNA polymerase (Figure 4B) and pristimerin did not
inhibit the mRNA of Sirt1 (an unrelated gene, Figure 4E).
These results suggest a relatively specific activity of pris-
timerin against Bcr-Abl mRNA. Further research will be
required to identify the precise mechanism by which
pristimerin decreases Bcr-Abl mRNA.
CML, being highly dependent on presence of Bcr-Abl,
is one of the typical models of oncogene addiction [43].
Inactivation of Bcr-Abl kinase by tyrosine kinase inhibi-
tors (e.g. imatinib, dasatinib) or downregulating the total
levels of cellular Bcr-Abl by pristimerin, triptolide [22]
and flavopiridol [33] (at the mRNA level), 17-AAG [44]
(at the protein level) could be effective approaches to
block "addictive oncogene" in Bcr-Abl-expressing cells.
Although pristimerin, triptolide, flavopiridol and 17-
AAG may impact multiple molecules, Bcr-Abl downreg-
ultion is the common effect and is likely the major factor
inducing apoptosis in Bcr-Abl-expressing cells. The
decrease of Bcr-Abl preceded the onset of apoptosis, sug-
gesting that Bcr-Abl may be the cause and not a conse-
quence of apoptosis in CML cells. Nevertheless,
pristimerin is effective in killing imatinib-resistant CML
cells bearing T315I Bcr-Abl. Furthermore, pristimerin
may be effective against CML cells bearing the Bcr-Abl
with mutations other than T315I because of its effect on
Bcr-Abl mRNA, and this remains to be confirmed. It also
remains to be investigated whether pristimerin has activ-
ity against CML stem cells, which is believed to be a criti-
cal cause of imatinib-resistance and an obstacle to curing
CML.
Pristimerin has been tested in vivo by us (Figure 5) and
others [20]. Suppression of tumor growth in mice treated
with pristimerin without causing death of the mice is
proof that a therapeutic window exists. The cytotoxicity
of pritimerin against normal bone marrow cells suggests
that bone marrow suppression may be a potential side
effect of pristimerin. The translational potential of pris-
timerin to clinical use will depend on its toxicity profile in
Phase I trials. At the very least, pritimerin is a lead com-
pound for further development of triterpenoid-derived
anticancer agents. In the future, it will be interesting to
examine whether bone marrow protective agents are
helpful in counteracting this side effect of pristimerin.
Modifying the structure of pristimerin may be an alterna-
tive approach to decrease the toxicity of the compound.
Conclusions
I n  s u m m a r y ,  o u r  f i n d i n g s  t o g e t h e r  s h o w e d  t h a t  p r i s -
timerin had an activity against CML cells bearing wild-
type or Bcr-Abl-T315I mutation. The mechanisms might
involve inhibition of NF-κB and Bcr-Abl. We concluded
that pristimerin could be a lead compound that merited
further development to overcome the imatinib-resistance
of CML patients.
Additional material
Abbreviations
AIF: apoptosis-inducing factor; ALL: acute lymphoid leukemia; AML: acute
myelogeneous leukemia; CML: chronic myelogeneous leukemia; EMSA: elec-
trophoretic mobility shift assay; FCS: fetal calf serum; JMML: juvenile myelo-
monocytic leukemia; NF-κB: nuclear factor κB; PCNA: proliferating cell nuclear
antigen; RT-qPCR: reverse transcription quantitative real-time PCR; TNFα: tumor
necrosis factor α.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
ZL performed experiments presented in Figures 4, 5, 6, 7; YJ performed experi-
ments presented in Figures 1, 2, 3, 4; CC and JL provided leukemia patient
specimens and relevant clinical data, and analyzed the data; QC performed
experiments of RT-qPCR in Figure 4E; JP designed, performed research, ana-
lyzed data, directed the whole study and wrote the manuscript. All the authors
read and proved the final manuscript.
Acknowledgements
We thank Drs. Mong-Hong Lee (The University of Texas MD Anderson Cancer 
Center) and Shilai Bao (Institute of Genetics and Developmental Biology, Chi-
nese Academy of Sciences) for generously providing plasmids of pNF-κB-luc, 
pCMV5-IKKα, pCMV5-IKKβ, pCMV5-IKKγ, pCMV5-p65, and pCMV5-myc-TAK1. 
This study was supported by grants from the National High Technology 
Research and Development Program of China (863 Program grant 
2008AA02Z420 to J. Pan), the Major Research Plan of the National Natural Sci-
ence Fund of China (grant 90713036 to J. Pan), and the National Basic Research 
Program of China (973 Program grant 2009CB825506 to J. Pan). The authors 
thank Dr. S. C. J. Yeung (The University of Texas M. D. Anderson Cancer Center, 
Houston, TX, USA) for a critical reading of the manuscript.
Author Details
1Department of Pathophysiology, Zhongshan School of Medicine, Sun Yat-sen 
University, Guangzhou, PR China, 2Department of Pediatrics, Sun Yat-sen 
memorial Hospital, Sun Yat-sen University, Guangzhou, PR China and 
3Department of Hematology, The First Affiliated Hospital, Sun Yat-sen 
University, Guangzhou, PR China
Additional file 1 Table S1. Characteristics of patients with leukemia. Sum-
mary of clinical characteristics of patients with leukemia.
Received: 19 February 2010 Accepted: 19 May 2010 
Published: 19 May 2010
This article is available from: http://www.molecular-cancer.com/content/9/1/112 © 2010 Lu et al; licensee BioMed Central Ltd.  This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Molecular Cancer 2010, 9:112Lu et al. Molecular Cancer 2010, 9:112
http://www.molecular-cancer.com/content/9/1/112
Page 16 of 17
References
1. Melo JV, Barnes DJ: Chronic myeloid leukaemia as a model of disease 
evolution in human cancer.  Nat Rev Cancer 2007, 7:441-453.
2. Quintas-Cardama A, Cortes J: Molecular biology of bcr-abl1-positive 
chronic myeloid leukemia.  Blood 2009, 113:1619-1630.
3. Quintas-Cardama A, Kantarjian H, Cortes J: Flying under the radar: the 
new wave of BCR-ABL inhibitors.  Nat Rev Drug Discov 2007, 6:834-848.
4. Lugo TG, Pendergast AM, Muller AJ, Witte ON: Tyrosine kinase activity 
and transformation potency of bcr-abl oncogene products.  Science 
1990, 247:1079-1082.
5. Baselga J, Arribas J: Treating cancer's kinase 'addiction'.  Nat Med 2004, 
10:786-787.
6. Druker BJ: Circumventing resistance to kinase-inhibitor therapy.  N Engl 
J Med 2006, 354:2594-2596.
7. Druker BG, O'Brien SRL: Long-term benefits of imatinib (IM) for patients 
newly diagnosed with chronic myelogenous leukemia in chronic 
phase (CML-CP):The 5-year update from the IRIS study [Abstract].  J Clin 
Oncol 2006, 24:18S.
8. Kantarjian HM, Talpaz M, Giles F, O'Brien S, Cortes J: New insights into the 
pathophysiology of chronic myeloid leukemia and imatinib resistance.  
Ann Intern Med 2006, 145:913-923.
9. Morinaga K, Yamauchi T, Kimura S, Maekawa T, Ueda T: Overcoming 
imatinib resistance using Src inhibitor CGP76030, Abl inhibitor 
nilotinib and Abl/Lyn inhibitor INNO-406 in newly established K562 
variants with BCR-ABL gene amplification.  Int J Cancer 2008, 
122:2621-2627.
10. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, O'Cortes J, 
Brien S, Nicaise C, Bleickardt E, Blackwood-Chirchir MA, Iyer V, Chen TT, 
Huang F, Decillis AP, Sawyers CL: Dasatinib in imatinib-resistant 
Philadelphia chromosome-positive leukemias.  N Engl J Med 2006, 
354:2531-2541.
11. Kaur P, Feldhahn N, Zhang B, Trageser D, Muschen M, Pertz V, Groffen J, 
Heisterkamp N: Nilotinib treatment in mouse models of P190 Bcr/Abl 
lymphoblastic leukemia.  Mol Cancer 2007, 6:67.
12. Lounnas N, Frelin C, Gonthier N, Colosetti P, Sirvent A, Cassuto JP, Berthier 
F, Sirvent N, Rousselot P, Dreano M, Peyron JF, Imbert V: NF-kappaB 
inhibition triggers death of imatinib-sensitive and imatinib-resistant 
chronic myeloid leukemia cells including T315I Bcr-Abl mutants.  Int J 
Cancer 2009, 125:308-317.
13. Guzman ML, Rossi RM, Neelakantan S, Li X, Corbett CA, Hassane DC, 
Becker MW, Bennett JM, Sullivan E, Lachowicz JL, Vaughan A, Sweeney CJ, 
Matthews W, Carroll M, Liesveld JL, Crooks PA, Jordan CT: An orally 
bioavailable parthenolide analog selectively eradicates acute 
myelogenous leukemia stem and progenitor cells.  Blood 2007, 
110:4427-4435.
14. Staudt LM: The molecular and cellular origins of Hodgkin's disease.  J 
Exp Med 2000, 191:207-212.
15. Guzman ML, Neering SJ, Upchurch D, Grimes B, Howard DS, Rizzieri DA, 
Luger SM, Jordan CT: Nuclear factor-kappaB is constitutively activated 
in primitive human acute myelogenous leukemia cells.  Blood 2001, 
98:2301-2307.
16. Kirchner D, Duyster J, Ottmann O, Schmid RM, Bergmann L, Munzert G: 
Mechanisms of Bcr-Abl-mediated NF-kappaB/Rel activation.  Exp 
Hematol 2003, 31:504-511.
17. Cilloni D, Messa F, Arruga F, Defilippi I, Morotti A, Messa E, Carturan S, 
Giugliano E, Pautasso M, Bracco E, Rosso V, Sen A, Martinelli G, Baccarani 
M, Saglio G: The NF-kappaB pathway blockade by the IKK inhibitor 
PS1145 can overcome imatinib resistance.  Leukemia 2006, 20:61-67.
18. Dirsch VM, Kiemer AK, Wagner H, Vollmar AM: The triterpenoid 
quinonemethide pristimerin inhibits induction of inducible nitric 
oxide synthase in murine macrophages.  Eur J Pharmacol 1997, 
336:211-217.
19. Costa PM, Ferreira PM, Bolzani S Vda, Furlan M, de Freitas Formenton 
Macedo Dos Santos VA, Corsino J, de Moraes MO, Costa-Lotufo LV, 
Montenegro RC, Pessoa C: Antiproliferative activity of pristimerin 
isolated from Maytenus ilicifolia (Celastraceae) in human HL-60 cells.  
Toxicol In Vitro 2008, 22:854-863.
20. Tiedemann RE, Schmidt J, Keats JJ, Shi CX, Zhu YX, Palmer SE, Mao X, 
Schimmer AD, Stewart AK: Identification of a potent natural 
triterpenoid inhibitor of proteosome chymotrypsin-like activity and 
NF-kappaB with antimyeloma activity in vitro and in vivo.  Blood 2009, 
113:4027-4037.
21. Wu CC, Chan ML, Chen WY, Tsai CY, Chang FR, Wu YC: Pristimerin induces 
caspase-dependent apoptosis in MDA-MB-231 cells via direct effects 
on mitochondria.  Mol Cancer Ther 2005, 4:1277-1285.
22. Shi X, Jin Y, Cheng C, Zhang H, Zou W, Zheng Q, Lu Z, Chen Q, Lai Y, Pan J: 
Triptolide inhibits Bcr-Abl transcription and induces apoptosis in 
STI571-resistant chronic myelogenous leukemia cells harboring T315I 
mutation.  Clin Cancer Res 2009, 15:1686-1697.
23. Lu Z, Jin Y, Qiu L, Lai Y, Pan J: Celastrol, a novel HSP90 inhibitor, depletes 
Bcr-Abl and induces apoptosis in imatinib-resistant chronic 
myelogenous leukemia cells harboring T315I mutation.  Cancer Lett 
2010, 290:182-191.
24. Jin Y, Lu Z, Ding K, Li J, Du X, Chen C, Sun X, Wu Y, Zhou J, Pan J: 
Antineoplastic mechanisms of niclosamide in acute myelogenous 
leukemia stem cells: inactivation of the NF-kappaB pathway and 
generation of reactive oxygen species.  Cancer Res 2010, 70:2516-2527.
25. Pan J, Quintas-Cardama A, Kantarjian HM, Akin C, Manshouri T, Lamb P, 
Cortes JE, Tefferi A, Giles FJ, Verstovsek S: EXEL-0862, a novel tyrosine 
kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast 
cells expressing the KIT D816V mutation.  Blood 2007, 109:315-322.
26. Blonska M, Shambharkar PB, Kobayashi M, Zhang D, Sakurai H, Su B, Lin X: 
TAK1 is recruited to the tumor necrosis factor-alpha (TNF-alpha) 
receptor 1 complex in a receptor-interacting protein (RIP)-dependent 
manner and cooperates with MEKK3 leading to NF-kappaB activation.  
J Biol Chem 2005, 280:43056-43063.
27. Jin Y, Lu Z, Cao K, Zhu Y, Chen Q, Zhu F, Qian C, Pan J: The antitumor 
activity of homoharringtonine against human mast cells harboring the 
KIT D816V mutation.  Mol Cancer Ther 2010, 9:211-223.
28. Pan J, She M, Xu ZX, Sun L, Yeung SC: Farnesyltransferase inhibitors 
induce DNA damage via reactive oxygen species in human cancer 
cells.  Cancer Res 2005, 65:3671-3681.
29. Sakurai H, Miyoshi H, Toriumi W, Sugita T: Functional interactions of 
transforming growth factor beta-activated kinase 1 with IkappaB 
kinases to stimulate NF-kappaB activation.  J Biol Chem 1999, 
274:10641-10648.
30. Anand P, Kunnumakkara AB, Harikumar KB, Ahn KS, Badmaev V, Aggarwal 
BB: Modification of cysteine residue in p65 subunit of nuclear factor-
kappaB (NF-kappaB) by picroliv suppresses NF-kappaB-regulated gene 
products and potentiates apoptosis.  Cancer Res 2008, 68:8861-8870.
31. Karin M: Nuclear factor-kappaB in cancer development and 
progression.  Nature 2006, 441:431-436.
32. Shambharkar PB, Blonska M, Pappu BP, Li H, You Y, Sakurai H, Darnay BG, 
Hara H, Penninger J, Lin X: Phosphorylation and ubiquitination of the 
IkappaB kinase complex by two distinct signaling pathways.  EMBO J 
2007, 26:1794-1805.
33. Chen R, Gandhi V, Plunkett W: A sequential blockade strategy for the 
design of combination therapies to overcome oncogene addiction in 
chronic myelogenous leukemia.  Cancer Res 2006, 66:10959-10966.
34. Yang H, Landis-Piwowar KR, Lu D, Yuan P, Li L, Reddy GP, Yuan X, Dou QP: 
Pristimerin induces apoptosis by targeting the proteasome in prostate 
cancer cells.  J Cell Biochem 2008, 103:234-244.
35. Birkenkamp KU, Geugien M, Schepers H, Westra J, Lemmink HH, Vellenga 
E: Constitutive NF-kappaB DNA-binding activity in AML is frequently 
mediated by a Ras/PI3-K/PKB-dependent pathway.  Leukemia 2004, 
18:103-112.
36. Dai Y, Rahmani M, Pei XY, Dent P, Grant S: Bortezomib and flavopiridol 
interact synergistically to induce apoptosis in chronic myeloid 
leukemia cells resistant to imatinib mesylate through both Bcr/Abl-
dependent and -independent mechanisms.  Blood 2004, 104:509-518.
37. Reuther JY, Reuther GW, Cortez D, Pendergast AM, Baldwin AS Jr: A 
requirement for NF-kappaB activation in Bcr-Abl-mediated 
transformation.  Genes Dev 1998, 12:968-981.
38. Tanaka A, Konno M, Muto S, Kambe N, Morii E, Nakahata T, Itai A, Matsuda 
H: A novel NF-kappaB inhibitor, IMD-0354, suppresses neoplastic 
proliferation of human mast cells with constitutively activated c-kit 
receptors.  Blood 2005, 105:2324-2331.
39. Griessinger E, Imbert V, Lagadec P, Gonthier N, Dubreuil P, Romanelli A, 
Dreano M, Peyron JF: AS602868, a dual inhibitor of IKK2 and FLT3 to 
target AML cells.  Leukemia 2007, 21:877-885.
40. Kiersnowska-Rogowska B, Izycka A, Jablonska E, Rogowski F, Parfienczyk 
A: Estimation of level of soluble form PECAM-1, ICAM-2 and TNF-alpha, 
IL-18 in serum patients with chronic myelogenic leukemia.  Przegl Lek 
2005, 62:772-774.Lu et al. Molecular Cancer 2010, 9:112
http://www.molecular-cancer.com/content/9/1/112
Page 17 of 17
41. Bhatia R, McGlave PB, Dewald GW, Blazar BR, Verfaillie CM: Abnormal 
function of the bone marrow microenvironment in chronic 
myelogenous leukemia: role of malignant stromal macrophages.  
Blood 1995, 85:3636-3645.
42. Pan J: RNA polymerase - an important molecular target of triptolide in 
cancer cells.  Cancer Lett 2010, 292:149-152.
43. Sawyers CL: Shifting paradigms, the seeds of oncogene addiction.  Nat 
Med 2009, 15:1158-1161.
44. An WG, Schulte TW, Neckers LM: The heat shock protein 90 antagonist 
geldanamycin alters chaperone association with p210bcr-abl and v-src 
proteins before their degradation by the proteasome.  Cell Growth Differ 
2000, 11:355-360.
doi: 10.1186/1476-4598-9-112
Cite this article as: Lu et al., Pristimerin induces apoptosis in imatinib-resis-
tant chronic myelogenous leukemia cells harboring T315I mutation by 
blocking NF-?B signaling and depleting Bcr-Abl Molecular Cancer 2010, 9:112